Phase I clinical trial of IPH2102/BMS-986015 in combination with ipilimumab announced

A Phase I study of the anti-KIR antibody IPH2102/BMS-986015 in combination with ipilimumab in patients with selected advanced solid tumors published on ClinicalTrials.gov

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that a second Phase I combination trial for IPH2102/BMS-986015 was published on the NIH website ClinicalTrials.gov: http://www.clinicaltrials.gov/ct2/show/NCT01750580.